Bioxytran Net Income
| BIXT Stock | USD 0.05 0 2.67% |
As of the 19th of February, Bioxytran shows the Risk Adjusted Performance of (0.01), mean deviation of 5.1, and Standard Deviation of 7.27. Bioxytran technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated thirteen technical drivers for Bioxytran, which can be compared to its peers.
Analyzing historical trends in various income statement and balance sheet accounts from Bioxytran's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bioxytran's valuation are summarized below:Bioxytran does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Bioxytran |
Bioxytran 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bioxytran's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bioxytran.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in Bioxytran on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding Bioxytran or generate 0.0% return on investment in Bioxytran over 90 days. Bioxytran is related to or competes with Mosaic Immunoengineerin. Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization... More
Bioxytran Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bioxytran's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bioxytran upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 40.67 | |||
| Value At Risk | (11.44) | |||
| Potential Upside | 12.92 |
Bioxytran Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bioxytran's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bioxytran's standard deviation. In reality, there are many statistical measures that can use Bioxytran historical prices to predict the future Bioxytran's volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.55) | |||
| Treynor Ratio | (0.42) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bioxytran's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bioxytran February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.41) | |||
| Mean Deviation | 5.1 | |||
| Coefficient Of Variation | (3,601) | |||
| Standard Deviation | 7.27 | |||
| Variance | 52.8 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.55) | |||
| Treynor Ratio | (0.42) | |||
| Maximum Drawdown | 40.67 | |||
| Value At Risk | (11.44) | |||
| Potential Upside | 12.92 | |||
| Skewness | 0.6613 | |||
| Kurtosis | 1.82 |
Bioxytran Backtested Returns
Bioxytran secures Sharpe Ratio (or Efficiency) of -0.11, which signifies that the company had a -0.11 % return per unit of risk over the last 3 months. Bioxytran exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Bioxytran's Mean Deviation of 5.1, risk adjusted performance of (0.01), and Standard Deviation of 7.27 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.51, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bioxytran's returns are expected to increase less than the market. However, during the bear market, the loss of holding Bioxytran is expected to be smaller as well. At this point, Bioxytran has a negative expected return of -0.69%. Please make sure to confirm Bioxytran's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Bioxytran performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.51 |
Modest predictability
Bioxytran has modest predictability. Overlapping area represents the amount of predictability between Bioxytran time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bioxytran price movement. The serial correlation of 0.51 indicates that about 51.0% of current Bioxytran price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.51 | |
| Spearman Rank Test | 0.29 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Bioxytran reported net income of (4.04 Million). This is 101.18% lower than that of the Biotechnology sector and 105.77% lower than that of the Health Care industry. The net income for all United States stocks is 100.71% higher than that of the company.
Bioxytran Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bioxytran's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Bioxytran could also be used in its relative valuation, which is a method of valuing Bioxytran by comparing valuation metrics of similar companies.Bioxytran is currently under evaluation in net income category among its peers.
Bioxytran Fundamentals
| Return On Asset | -7.04 | |||
| Current Valuation | 19.06 M | |||
| Shares Outstanding | 144.64 M | |||
| Shares Owned By Insiders | 65.60 % | |||
| Price To Sales | 532.56 X | |||
| EBITDA | (3.59 M) | |||
| Net Income | (4.04 M) | |||
| Cash And Equivalents | 500.68 K | |||
| Total Debt | 2.17 M | |||
| Current Ratio | 0.09 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (839.44 K) | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 2.71 | |||
| Beta | -0.43 | |||
| Market Capitalization | 17.21 M | |||
| Total Asset | 370.94 K | |||
| Retained Earnings | (11.22 M) | |||
| Working Capital | (3.37 M) | |||
| Z Score | -80.36 | |||
| Net Asset | 370.94 K |
About Bioxytran Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bioxytran's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioxytran using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioxytran based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bioxytran OTC Stock Analysis
When running Bioxytran's price analysis, check to measure Bioxytran's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioxytran is operating at the current time. Most of Bioxytran's value examination focuses on studying past and present price action to predict the probability of Bioxytran's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioxytran's price. Additionally, you may evaluate how the addition of Bioxytran to your portfolios can decrease your overall portfolio volatility.